Cargando…

Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature

A 69-year-old man with stage IIIB lung adenocarcinoma received durvalumab following chemoradiotherapy. The prescribed dose was 50 Gy in 2 Gy fractions, and the maximum spinal cord dose was 40 Gy. After three cycles of durvalumab, he experienced bladder and rectal disturbance, muscle weakness in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubo, Katsumaro, Wadasaki, Koichi, Yamane, Hiroaki, Doi, Mihoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545180/ https://www.ncbi.nlm.nih.gov/pubmed/31218187 http://dx.doi.org/10.1007/s13691-019-00367-5

Ejemplares similares

A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy
por: Kubo, Katsumaro, et al.
Publicado: (2019)

Hydrogel spacer shrinkage during external-beam radiation therapy following low-dose-rate brachytherapy for high-risk prostate cancer: a case series
por: Kubo, Katsumaro, et al.
Publicado: (2021)

Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
por: Wang, Lan, et al.
Publicado: (2021)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

Clinical features of prostate-specific antigen bounce after (125)I brachytherapy for prostate cancer
por: Kubo, Katsumaro, et al.
Publicado: (2018)

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
por: Mayahara, Hiroshi, et al.
Publicado: (2022)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
por: Saito, Satoshi, et al.
Publicado: (2020)

Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer
por: Pasquier, Corentin, et al.
Publicado: (2023)

Cases Illustrative of Syphilitic Meningo-Myelitis
por: Macgregor, G. Scott
Publicado: (1899)

Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma
por: Hirama, Nobuyuki, et al.
Publicado: (2023)

Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
por: Kawai, Shoko, et al.
Publicado: (2020)

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
por: Moodie, Travis, et al.
Publicado: (2022)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)

Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
por: Ochi, Masanori, et al.
Publicado: (2020)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
por: Uemura, Takehiro, et al.
Publicado: (2021)

Acquired amegakaryocytic thrombocytopenia after durvalumab administration
por: Suyama, Takahiro, et al.
Publicado: (2021)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer
por: Imano, Nobuki, et al.
Publicado: (2020)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
por: Pennock, Michael, et al.
Publicado: (2023)

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature
por: Carausu, Marcela, et al.
Publicado: (2019)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
por: Denault, Marie-Hélène, et al.
Publicado: (2022)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Predicting the Local Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant Chemoradiotherapy by Radiomics with a Machine Learning Method Using (18)F-FDG PET Images
por: Murakami, Yuji, et al.
Publicado: (2021)

Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
por: Kishi, Noriko, et al.
Publicado: (2022)

Volumetric-Modulated Arc Therapy for Giant-Cell Tumor of Temporal Bone: An Illustrative Case Report
por: Kubo, Katsumaro, et al.
Publicado: (2022)

Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2020)

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
por: Oshiro, Yoshiko, et al.
Publicado: (2021)

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
por: Mayadev, Jyoti, et al.
Publicado: (2020)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Effectiveness of robust optimization in volumetric modulated arc therapy using 6 and 10 MV flattening filter-free beam therapy planning for lung stereotactic body radiation therapy with a breath-hold technique
por: Miura, Hideharu, et al.
Publicado: (2020)

Transverse myelitis after Johnson & Johnson COVID-19 vaccine: illustrative case
por: Mathew, Ezek, et al.
Publicado: (2022)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
por: Pantarotto, Marcos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9v4lfiiari887k59g8ceo496u9